Trending

CGRP

After rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival Ajovy

After rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival Ajovy

Several months after turning down NHS funding for Novartis’ CGRP inhibitor Aimovig for migraine prevention, NICE has backed

X

After rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival Ajovy

https://pharmaphorum.com/news/novartis-aimovig-for-migraine-nice-backs-teva-rival/

CHMP turns down Lilly’s Emgality for cluster headache

CHMP turns down Lilly’s Emgality for cluster headache

An EMA advisory panel has rejected expanding the use of Eli Lilly’s Emgality to include prevention of episodic

X

CHMP turns down Lilly’s Emgality for cluster headache

https://pharmaphorum.com/news/chmp-turns-down-lillys-emgality-for-cluster-headache/

After rejection, NICE agrees to look again at migraine drug Aimovig

After rejection, NICE agrees to look again at migraine drug Aimovig

The UK’s medicines cost-effectiveness agency NICE has agreed to look again at its decision to turn down NHS

X

After rejection, NICE agrees to look again at migraine drug Aimovig

https://pharmaphorum.com/news/nice-migraine-aimovig/

Allergan builds case for migraine drug ubrogepant as FDA verdict nears

Allergan builds case for migraine drug ubrogepant as FDA verdict nears

Allergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved

X

Allergan builds case for migraine drug ubrogepant as FDA verdict nears

https://pharmaphorum.com/news/allergan-builds-case-for-migraine-drug-ubrogepant-as-fda-verdict-nears/

Sosei see Teva pipeline cull as an opportunity

Sosei see Teva pipeline cull as an opportunity

Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.

X

Sosei see Teva pipeline cull as an opportunity

https://pharmaphorum.com/news/sosei-loses-teva-culls-migraine-pipeline/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com